arrow
J

Jana Fassunke

University of Cologne
H指数:28
被引数:3,429

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass)

GUIDANCE试验的原理与设计方案:一项多中心II期临床试验,旨在评估标准一线治疗(卡铂/顺铂、依托泊苷和度伐利尤单抗)后,对HRD阳性广泛期(ED)小细胞肺癌(SCLC)患者进行度伐利尤单抗和奥拉帕利维持治疗的疗效(AIO-TRK-0124/ass)

2026-09-010
PRE
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations

携带KRAS Q61突变非小细胞肺癌(NSCLC)患者的分子和临床特征

2024-09-010
PRE
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancerdfinal results of the EUCROSS trial
2024-02-011
OAAI
Genomic ALK alterations in primary and relapsed neuroblastoma
2023-02-1726
OAAI
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors
2023-01-0119
PRE
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
2021-12-1716
OAAI
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
2018-11-07111
OAAI
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence
2018-10-0818
OAAI
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
2018-10-01130
OAAI
EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial
2017-09-0826
PREAI